Get the Stockscreener App
23.87
2.36%
0.55
Pre-market:
23.71
-0.16
-0.67%
Edgewise Therapeutics Inc stock is traded at $23.87, with a volume of 667.93K.
It is up +2.36% in the last 24 hours and up +37.78% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
See More
Previous Close:
$23.32
Open:
$23.44
24h Volume:
667.93K
Relative Volume:
0.65
Market Cap:
$2.53B
Revenue:
-
Net Income/Loss:
$-150.70M
P/E Ratio:
-15.40
EPS:
-1.55
Net Cash Flow:
$-125.67M
1W Performance:
-6.47%
1M Performance:
+37.78%
6M Performance:
+64.73%
1Y Performance:
-25.55%
1-Day Range:
$23.14
$24.04
1-Week Range:
$22.51
$26.30
52-Week Range:
$10.60
$35.50
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
23.87 | 2.47B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Goldman | Neutral |
| Jul-30-25 | Initiated | Raymond James | Strong Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 5.4%Should You Sell? - MarketBeat
XTX Topco Ltd Takes Position in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Sio Capital Management LLC Acquires New Position in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Edgewise Therapeutics reports inducement grants as permitted by the Nasdaq Listing Rules - marketscreener.com
Edgewise Therapeutics (Nasdaq: EWTX) issues inducement option for 26,250 shares at $26.04 - Stock Titan
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Geode Capital Management LLC Raises Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Is Edgewise Therapeutics Inc a good long term investmentHigh Dividend Yield Stocks & High Yield Portfolio Growth - earlytimes.in
[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity - Stock Titan
Edgewise Therapeutics Appoints Christopher Martin to Board - MSN
Will Edgewise Therapeutics (EWTX) Gain a Commercial Edge With Its New Board Appointment? - sahmcapital.com
Edgewise Therapeutics adds commercial biotech exec Martin to board - Investing.com
Edgewise Therapeutics adds commercial biotech exec Martin to board By Investing.com - Investing.com Nigeria
Edgewise Therapeutics Appoints Christopher Martin as Director - TradingView
[8-K] Edgewise Therapeutics, Inc. Reports Material Event | EWTX SEC FilingForm 8-K - Stock Titan
Edgewise Therapeutics appoints commercial biotech executive Christopher Martin to its Board of Directors - marketscreener.com
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin To Its Board Of Directors - TradingView
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors - WV News
What is the fair value of Edgewise Therapeutics Inc. stock now2025 Market Outlook & Daily Stock Trend Watchlist - newser.com
What recovery options are there for Edgewise Therapeutics Inc.Quarterly Performance Summary & Accurate Trade Setup Notifications - newser.com
Multi asset correlation models including Edgewise Therapeutics Inc.Weekly Trading Summary & Daily Profit Focused Stock Screening - newser.com
Exit strategy if you’re trapped in Edgewise Therapeutics Inc.Earnings Overview Report & Short-Term High Return Ideas - newser.com
How to track smart money flows in Edgewise Therapeutics Inc.July 2025 Breakouts & Safe Entry Point Identification - newser.com
Will Edgewise Therapeutics’ (EWTX) New CFO Mark a Shift in Its Commercial Strategy? - Yahoo Finance
Edgewise Therapeutics (EWTX): Assessing Valuation After Clinical Progress and New CFO Appointment - sahmcapital.com
What valuation multiples suggest for Edgewise Therapeutics Inc. stockPrice Action & Free Technical Confirmation Trade Alerts - newser.com
Shareholder Carruthers Files To Sell 70,000 Of Edgewise Therapeutics Inc [EWTX] - TradingView
Order flow analysis tools used on Edgewise Therapeutics Inc.GDP Growth & Weekly Top Gainers Trade List - newser.com
Edgewise Therapeutics chief business officer sells $300,300 in stock - MSN
Edgewise Therapeutics (EWTX) Reports Heightened R&D Activity in Q3 2025 - Insider Monkey
Published on: 2025-11-16 12:13:56 - newser.com
What drives Edgewise Therapeutics Inc stock priceGeopolitical Risk Analysis & Low Cost Capital Trading - earlytimes.in
Risk adjusted return profile for Edgewise Therapeutics Inc. analyzedCEO Change & Technical Confirmation Alerts - newser.com
Real time breakdown of Edgewise Therapeutics Inc. stock performance2025 Market Sentiment & Risk Adjusted Buy and Sell Alerts - newser.com
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):